Clinical Trial

Bazedoxifene -Treatment for Women With Schizophrenia

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-10-01; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2020-01-06
Trial Details
NCT Number NCT04113993
Lead Sponsor The Alfred
Collaborators: Monash University
Conditions Schizophrenia, Schizophreniform Disorders, Schizo Affective Disorder
Enrollment 160 participants
Start Date 2019-10-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03